ING2 (ING1Lp): A Potential Drug Target for Neurological and Psychiatric Diseases

Target Name: ING2

NCBI ID: G3622

ING2

ING2 (ING1Lp): A Potential Drug Target for Neurological and Psychiatric Diseases

ING2 (ING1Lp) is a protein that is expressed in the nervous system and has been shown to play a role in various neurological conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The ING2 gene has also been implicated in several diseases, including cancer, and its function is still not well understood.

ING2 (ING1Lp) is a transmembrane protein that is expressed in the nervous system, including the brain. It is a member of the T-cell receptor (TCR) family and is involved in the development and maintenance of the immune system. ING2 is also known as CD1A, and its function is related to the development and regulation of T cells, which are a crucial part of the immune system.

ING2 (ING1Lp) has been shown to play a role in several neurological conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is also associated with the development of certain cancers, including breast and ovarian cancer.

ING2 (ING1Lp) has been shown to interact with several other proteins, including the protein PD-L1. PD-L1 is a protein that is expressed in many types of cancer, including breast and ovarian cancer. It is known for its ability to suppress the immune system, and it has been implicated in the development of cancer.

ING2 (ING1Lp) has also been shown to interact with the protein NF-kappa-B. NF-kappa-B is a protein that is involved in inflammation and immune responses. It is known for its ability to promote the growth and survival of cancer cells, and it is a potential target for cancer treatments.

ING2 (ING1Lp) is a potential drug target (or biomarker) for several neurological and psychiatric diseases. Its function in the immune system and its interaction with other proteins that are involved in disease development make it an attractive target for researchers and clinicians.

ING2 (ING1Lp) is a transmembrane protein that is expressed in the nervous system and is involved in the development and regulation of T cells. It is also associated with the development of certain cancers, including breast and ovarian cancer. Its function is not well understood, but it is known for its role in the immune system and its interaction with other proteins that are involved in disease development.

Conclusion

ING2 (ING1Lp) is a protein that is expressed in the nervous system and is involved in the development and regulation of T cells. It is also associated with the development of certain cancers, including breast and ovarian cancer. Its function is not well understood, but it is known for its role in the immune system and its interaction with other proteins that are involved in disease development. As a potential drug target (or biomarker) for several neurological and psychiatric diseases, ING2 (ING1Lp) is a promising target for future research and clinical trials.

Protein Name: Inhibitor Of Growth Family Member 2

Functions: Seems to be involved in p53/TP53 activation and p53/TP53-dependent apoptotic pathways, probably by enhancing acetylation of p53/TP53. Component of a mSin3A-like corepressor complex, which is probably involved in deacetylation of nucleosomal histones. ING2 activity seems to be modulated by binding to phosphoinositides (PtdInsPs)

The "ING2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ING2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets